Kura Oncology, Inc. (NASDAQ: KURA) received a $135 million milestone payment for the U.S. commercial sale of KOMZIFTI, an oral targeted therapy for certain types of leukemia. Early trial results showed KOMZIFTI combined with other drugs was well tolerated and effective in treating relapsed or refractory leukemia. While KURA presents investment potential, other AI stocks may offer greater upside potential and less downside risk. For more information on promising AI stocks, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Jim Cramer Discusses Kura Oncology as a Speculative Bet